Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 4
Submit an article Journal homepage
108
Views
11
CrossRef citations to date
0
Altmetric
Review

Emerging therapies in multiple sclerosis

Rachel Farrell Institute of Neurology, Department of Neuroinflammation, Queen Square, London, WC1N 3BG, UK. [email protected]
,
Dominic Heaney Institute of Neurology, Department of Neuroinflammation, Queen Square, London, WC1N 3BG, UK. [email protected]
&
Gavin Giovannoni Institute of Neurology, Department of Neuroinflammation, Queen Square, London, WC1N 3BG, UK. [email protected]
Pages 797-816 | Published online: 31 Oct 2005

Bibliography

  • COMPSTON A, COLES A: Multiple sclerosis. Lancet (2002) 359:1221–1231.
  • KURTZKE JF: Epidemiology and multiple sclerosis. Rev. Neurol (2002) 35:1177.
  • MARRIE RA: Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol (2004) 3(12):709–718.
  • WILLER CJ, DYMENT DA, RISCH NJ, SADOVNICK AD, EBERS GC; CANADIAN COLLABORATIVE STUDY GROUP: Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl. Acad. Sci. USA (2003) 100(22):12877–12882.
  • MARTYN CN, GALE CR: The epidemiology of multiple sclerosis. Acta Neurol Scand. Suppl. (1997) 169:3–7.
  • GALE CR, MARTYN CN: Migrant studies in multiple sclerosis. Prog NeurobioL (1995) 47:425–448.
  • GILDEN DH: Infectious causes of multiple sclerosis. Lancet Neurol (2005) 4(3):195–202.
  • KURTZKE JF, HYLLESTED K: Multiple sclerosis in the Faroe Islands: I. Clinical and epidemiological features. Ann. Neurol. (1979) 5(1):6–21.
  • SAUL RF, HAYAT G, SELHORST JB: Visual evoked potentials during hyperthermia. j Neuroophthalmol (1995) 15(2):70–78.
  • MCDONALD WI, COMPSTON A. EDAN G et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. (2001) 50(1):121–127.
  • MILLER D, BARKHOF F, MONTALBAN X, THOMPSON A, FILIPPI M: Clinically isolated syndromes suggestive of multiple sclerosis, part I: naturalhistory, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 4(5):281–288.
  • MILLER D, BARKHOF F, MONTALBAN X, THOMPSON A, FILIPPI M: Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol. (2005) 4(6):341–348.
  • TRAPP BD, PETERSON J, RANSOHOFF RM, RUDICK R, MORK S, BO L: Axonal transection in the lesions of multiple sclerosis. N Engl. J. Med. (1998) 338(5):278–285.
  • JACOBS LD, BECK RW, SIMON JH et al.: Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group. N Engl. J. Med. (2000) 343(13):898–904.
  • SOSPEDRA M, MARTIN R: Immunologyof multiple sclerosis. Ann. Rev. Immunol (2005) 23:683-747. Review of immunology MS.
  • BARNETT MH, PRINEAS JW: Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol (2004) 55(4):458–468. Important pathological study. Alters our understanding of pathophysiology.
  • PETERSON JW, BO L, MORK S, CHANG A, TRAPP BD: Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol (2001) 50(3):389–400.
  • LASSMANN H, BRUCK W, LUCHINETTI C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med. (2001) 7(3):115–121.
  • FOOTE AK, BLAKEMORE WF: Inflammation stimulates remyelination in areas of chronic demyelination. Brain (2005) 128(Pt 3):528–539.
  • HARTUNG HP, BAR-OR A. ZOUKUS Y:What do we know about the mechanism of action of disease-modifying treatments in MS?J. Neurol. (2004) 251\(Suppl. 5):v12-v29. Good review of existing treatments and mechanism of action.
  • HEMMER B, CEPOK S, NESSLER S, SOMMER N: Pathogenesis of multiple sclerosis: an update on immunology. Curr. Opin. Neurol. (2002) 15(3):227–231.
  • WOLINSKY JS; PROMiSe TRIAL STUDY GROUP: The PROMiSe trial: baseline data review and progress report. Mult. Scler. (2004) 10\(Suppl. 1):565–571.
  • LEARY SM, MILLER DH, STEVENSON V1,, BREX PA, CHARD DT, THOMPSON AJ: Interferon beta-la in primary progressive MS: an exploratory, randomized,controlled trial. Neurology (2003) 60(1):44–51.
  • MONTALBAN X: Overview of European pilot study of interferon-Bib in primary progressive multiple sclerosis. Mult. Scler. (2004) 10\(Suppl. 1):562.
  • LEPPERT D, WAUBANT E, BURK MR, OKSENBERG JR, HAUSER SL: Interferon-Blb inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. (1996) 40(6):846–852.
  • IFNI3 MULTIPLE SCLEROSIS STUDY GROUP: Interferon-Bib is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology (1993) 43:655–661.
  • JACOBS LD, COOKFAIR DL, RUDICK RA et al.; THE MULTIPLE SCLEROSIS COLLABORATIVE RESEARCH GROUP: Intramuscular interferon-Bia for disease progression in relapsing multiple sclerosis. Ann. Neurol (1996) 39:285–294.
  • PRISMS STUDY GROUP: Randomised,double-blind, placebo-controlled study of interferon-Bia in relapsing/remitting multiple sclerosis. Lancet (1998) 352:1498–1504.
  • MUNSCHAUER FE, KINKEL RP: Managing side effects of interferon beta in patients with relapsing-remitting multiple sclerosis. Clin. Ther. (1997) 19:883–893.
  • MALUCCHI S, SALA A, GILLI F et al.: Neutralizing antibodies reduce the efficacy of betaIEN during treatment of multiple sclerosis. Neurology (2004) 62:2031–2037.
  • BERTOLOTTO A, GILLI F, SALA A et al.: Persistent neutralizing antibodies abolish the interferon-I3 bioavailability in MS patients. Neurology (2003) 60:634–639.
  • COOK SD, QUINLESS JR, JOTKOWITZ A, BEATON P: Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology (2001) 57:1080–1084.
  • PANITCH H, GOODIN DS, FRANCIS G et al.: Randomized, comparative study of interferon-Bla treatment regimens in MS: The EVIDENCE Trial. Neurology (2002) 59:1496–1506.
  • NO AUTHORS LISTED: Neutralizing antibodies during treatment of multiple sclerosis with interferon-Blb: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology (1996) 47:889–894.
  • TEITELBAUM D, AHARONI R, KLINGER E et al.: Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Ann. NY Acad. Sci. (2004) 1029:239–249.
  • TEITELBAUM D, AHARONI R, ARNON R, SELA M: Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc. Natl. Acad. Sci. USA (1988) 85(24):9724–9728.
  • MILLER A, SHAPIRO S, GERSHTEIN R et al: Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of TH1 to TH2/TH3 immune-deviation. J. Neuroimmunol (1998) 92(1-2):113–121.
  • KIM HJ, IFERGAN I, ANTEL JP et al: Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol (2004) 172(11):7144–7153.
  • STADELMANN C, KERSCHENSTEINER M, MISGELD T, BRUCK W, HOHLFELD R, LASSMANN H: BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain (2002) 125:75–85.
  • ZIEMSSEN T, KUMPFEL T, KLINKERT WE, NEUHAUS O, HOHLFELD R: Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain (2002) 125:2381–2391.
  • AHARONI R, KAYHAN B, EILAM R, SELA M, ARNON R: Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl Acad. Sci. USA (2003) 100(24):14157–14162.
  • MILLER DM, WEINSTOCK-GUTTMAN B, BETHOUX F et al: A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult. Scler. (2000) 6(4):267–273.
  • BRUSEFERRI F, CANDELISE L: Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J. Neurol (2000) 247(6):435–442.
  • MILLER DH, THOPMSON AJ, MORRISSEY SP et al: High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J. Neurol Neurosurg. Psychiatry (1992) 55(6):450–453.
  • BARKHOF F, HOMMES OR, SCHELTENS P, VALK J: Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology (1991) 41(8):1219–1222.
  • OLIVIERI RL, VALENTINO P, RUSSO C et al.: Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology (1998) 50(6):1833–1836.
  • ZIVADINOV R, RUDICK R, DE MASI R et al.: Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology (2001) 57:1239–1247.
  • GOODKIN DE, KINKEL RP, WEINSTOCK-GUTTMANN B et al: A Phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology (1998) 51(1):239–245.
  • GASPERINI C, POZZILLI C, BASTIANELLO S et al: Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon la treatment in relapsing remitting multiple sclerosis. Neurology (1998) 50(2):403–406.
  • RICHERT ND, OSTUNI JL, BASH CN, LEIST TP, MCFARLAND HF, FRANK JA: Interferon-Blb and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult. Scler. (2001) 7(1):49–58.
  • POZZILLI C, ANTONINI G, BAGNATO F: Monthly corticosteroids decrease neutralizing antibodies to IFN-Bib: a randomized trial in MS. J. Neurol (2002) 249:50–56.
  • LUBLIN FD, LAVASA M, VITT C, KNOBLER RL: Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immunol Immunopathol (1987) 45(1):122–128.
  • EDAN G, MILLER D, CLANET M et al: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol Neurosurg. Psychiatry (1997) 62(2):112–118.
  • HARTUNG HP, GONSETTE R, KONIG N et al; MITOXANTRONE IN MULTIPLE SSCLEROSIS STUDY GROUP (MIMS): Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (2002) 360(9350):2018–2025.
  • FIDLER JM, DEJOY SQ, GIBBONS JJ Jr: Selective immunomodulation by the antineoplastic agent mitoxantrone. Suppression of B lymphocyte function. Immunol (1986) 137(2):727–732.
  • GHALIE RG, MAUCH E, EDAN G et al: Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology (2002) 59:909–913.
  • BRASSAT D, RECHER C, WAUBANT E et al.: Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with MS. Neurology (2002) 59:954–955.
  • GHALIE RG, EDAN G, LAURENT M et al.: A study of therapy-related acute leukaemia after mitoxantrone therapy for MS. Mult. Scler. (2002) 5:441–445.
  • EDAN G: Immunosuppressive therapy in multiple sclerosis. Neurol Sci. (2005) 26\(Suppl. 1):s18.
  • EDAN G et al.: Use of Mitoxantrone to treat MS, Chapter 25. In: MS Therapeutics, 2nd Edition. Martin Dunitz, London (2003).
  • YUDKIN PL, ELLISON GW, GHEZZI et al.: Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 338(8774):1051–1055.
  • PALACE J, ROTHWELL P: New treatments and azathioprine in MS. Lancet (1997) 350(9073):261.
  • SMITH D: Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. J. Neurol. Sci. (2004) 223(1):73–79.
  • PATTI F, AMATO MP, FILIPPI M, GALLO P, TROJANO M, COMI GC: A double blind, placebo-controlled, Phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J. Neurol. Sci. (2004) 223(1):69–71.
  • GOODKIN D, RUDICK RA, VANDERBRUG MEDENDORP S et al: Low-dose (7,5mg) oral methotrexate reduces the rate of progression in chronic progressive MS. Ann. Neurol (1995) 37:30–40.
  • CALABRESI PA, WILTERDINK JL, ROGG JM, MILLS P, WEBB A, WHARTENBY KA: An open-label trial of combination therapy with interferon-01a and oral methotrexate in MS. Neurology (2002) 58(2):314–317.
  • DALAKAS MC: Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology (1998) 51(6 Suppl. 5):52–58.
  • SORENSEN PS, WANSCHER B, JENSEN CV et al.: Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology (1998) 50(5):1273–1281.
  • ACHIRON A, GABBAY U, GILAD R et al.: Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology (1998) 50(2):398–402.
  • ACHIRON A, KISHNER I, SAROVE-PINHAS I et al.: Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch. Neurol (2004) 61(10):1515–1520.
  • LEWANSKA M, SIGER-ZADJEL M, SELMAJ K: No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Fur. J. Neurol (2002) 9(6):565–572.
  • FAZEKAS F, DEISENHAMMER F, STRASSER-FUCHS S, NAHLER G, MAMOLI B: Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study. Mult. Scler. (1997) 3(2):137–141.
  • KOCER B, YILDIRIM-GUREL S, TALI ET, IRKEC C, ISIK S: The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G. Neuroradiology (2004) 46(4):287–290.
  • SORENSEN PS, FAZEKAS F, LEE M: Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Fur. J. Neurol (2002) 9(6):557–563.
  • HOMMES OR, SORENSEN PS, FAZEKAS F et al.: Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet (2004) 364(9440):1149–1156.
  • ROED HG, LANGKILDE A, SELLEBJERG F et al.: A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology (2005) 64(5):804–810.
  • FRENETTE PS, WAGNER DD: Adhesion molecules - Part II: blood vessels and blood cells. N Engl. J. Med. (1996) 335(1):43–45.
  • TUBRIDY N, BEHAN PO, CAPILDEO R et al.: The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 53(3):466–472.
  • MILLER DH, KHAN OA, SHEREMATA WA et al; INTERNATIONAL NATALIZUMAB MULTIPLE SCLEROSIS TRIAL GROUP: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl. J. Med. (2003) 348(1):15–23.
  • PAOLILLO A, COLES A, MOLYNEUX P et al.: Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology (1999) 53:751.
  • COLES A, DEANS J, COMPSTON k Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin. Neurol Neurosurg. (2004) 106(3):270–274.
  • MOREAU T, COLES A, WING M et al: Transient increase in symptoms associated with cytokine release in patients with MS. Brain (1996) 119:225–237.
  • COLES AJ, WING M, SWITH S et al: Pulsed monoclonal antibody treatment and autoimmune thyroid disease in MS. Lancet (1999) 354(9191):1691–1695.
  • WALDMANN TA, O'SHEA J: The use of antibodies against the IL-2 receptor in transplantation. Curr. Opin. Immunol (1998) 10(5):507–512.
  • VINCENTI F, KIRKMAN R, LIGHTS et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl. J. Med. (1998) 338(3):161–165.
  • ROSE J, LORBERBOUM-GALASKI H, FITZGERALD D et al.: Chimeric cytotoxin 1L2-PE40 inhibits relapsing experimental allergic encephalomyelitis. Neuroimmuno/ogy (1991) 32:209–217.
  • BIELEKOVA B, RICHERT N, HOWARD T et al: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Nail. Acad. Sci. USA (2004) 101(23):8705–8708.
  • ROSE JW, WATT HE, WHITE AT, CARLSON NG: Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol (2004) 56(6):864–867.
  • ARCHELOS JJ, STORCH MK, HARTUNG HP: The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. (2000) 47(6):694–706.
  • PESTRONK A, FLORENCE J, MILLER T, CHOKSI R, AL-LOZI MT, LEVINE TD: Treatment of IgM antibody associated polyneuropathies using rituximab. j Neurol. Neurosurg. Psychiatry (2003) 74(4):485–489.
  • YOUSSEF S, STUVE O, PATARROYO JC et al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a TH2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 420(6911):78–84.
  • GREENWOOD J, WALTERS CE, PRYCE G et al.: Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. (2003) 17(8):905–907.
  • NEUHAUS O, STRASSER-FUCHS S, FAZEKAS F et al.: Statins as immunomodulators: comparison with interferon-beta lb in MS. Neurology (2002) 59(7):990–997.
  • SENA A, PEDROSA R, GRACA MORAIS M: Therapeutic potential of lovastatin in multiple sclerosis. Neurol (2003) 250(0:754–755.
  • VOLLMER T, KEY L, DURKALAKSI V et al.: Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet (2004) 363(9421):1607–1608.
  • SEHGAL SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. (2003) 35(3 Suppl.):75–145.
  • CONFAVREUX C, HUTCHINSON M, HOURS MM, CORTINOVIS-TOURNIAIRE P, MOREAU T: Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J. Med. (1998) 339(5):285–291.
  • KRISHNAN L, GUILBERT LJ, RUSSELL AS, WEGMANN TG, MOSMANN TR, BELOSOVIC M: Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-y response and increased production of T helper 2 cytokines. j Immunol (1996) 156(2):644–652.
  • KIM S, LIVA SM, DALAL MA, VERITY MA, VOSHKUL RR: Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology (1999) 52(6):1230–1238.
  • SICOTTE NL, LIVA SM, KLUTCH R et al.: Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol (2002) 52(4):421–428.
  • SUZUMURA A, SAWADA M, MAKINO M, TAKAYANGI T: Propentofylline inhibits production of TNFalpha and infection of LP-BM5 murine leukemia virus in glial cells. Neurovirol (1998) 5:553–559.
  • SUZUMURA A, ITO A, YOSHIKAWA M, SAWADA M: Ibudilast suppresses TNF-a production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. (1999) 837(1–2):203-212.
  • FUJIMOTO T, SAKODA S, FUJIMURA H, YANAGIHARA T: Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. Neuroimmunol (1999) 95(1-2):35–42.
  • GERMAIN RN, STEFANOVA I: The dynamics of T-cell receptor signalling: complex orchestration and the key roles of tempo and cooperation. Ann. Rev. Immunol (1999) 17:467–522.
  • BIELEKOVA B, GOODWIN B, RICHERT N et al: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat. Med. (2000) 10:1167–1175.
  • KAPPOS L, COMI G, PANITCH H et al.: Induction of a non-encephalitogenic Type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo- controlled, randomized Phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. (2000) 10:1176–1182.
  • SHUKALIAK QUANDT J, BORRAS E, PRAT E et al.: Peptidic complex mixtures as therapeutic agents in CNS autoimmunity. Mol Immunol (2004) 40(14-15):1075–1087.
  • VANDENBARK AA, CHOU YK, WHITHAM R et al: Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. (1996) 10:1109–1115.
  • VANDENBARK AA, VAINIENE M, ARIAIL K, MILLER SD, OFFNER H: Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes. J. Neurosci. Res. (1996) 45(4):430–438.
  • BOURDETTE DN, WHITHAM RH, CHOU YK et al.: Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J. Immunol (1994) 152(5):2510–2519.
  • MORGAN EE, NARDO CJ, DIVELEY JP et al.: Vaccination with a CDR2 BV652/ 6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. J. Neurosci. Res. (2001) 64(3):298–301.
  • HERMANS G, DENZER U, LOHSE A, RAUS J, STINESSEN P: Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T-cell vaccination. J. Autoimmun. (1999) 13(2):233–246.
  • ZHANG JZ, RIVERA VM, TEJADA-SIMON MV: T-cell vaccination in multiple sclerosis: results of a preliminary study. J. Neurol. (2002) 249(2):212–218.
  • ACHIRON A, LAVIE G, KISHNER I et al.: T-cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin. Immunol (2004) 113(2):155–160.
  • KORN T, MAGNUS T, TOKYA K, JUNG S: Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion. J. Leukoc. Biol. (2004) 76:950–960.
  • NAKAJIMA A, YAMANAKA H, KAMATANI N: [Leflunomide: Clinical effectiveness and mechanism of action]. Clin. Calcium. (2003) 13(0:771–775.
  • KORN T, TOYKA K, HARTUNG HP, JUNG S: Suppression of experimental autoimmune neuritis by leflunomide. Brain (2001) 124:1791–1802.
  • YAO HW, LI J, CHEN JQ, XU SY: A 771726, the active metabolite of leflunomide, inhibits TNF-a and IL-1 from Kupffer cells. Inflammation (2004) 28(2):97–103.
  • SMOLEN JS, EMERY P, KALDEN JR et al.: The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J. Rheumatol Suppl. (2004) 71:13–20.
  • LI DKB, O'CONNOR P, FREEDMAN M et al; on behalf of the TERIFLUNOMIDE MULTIPLE SCLEROSIS TRIAL GROUP: Preliminary results teriflunomide. Oral teriflunomide is safe and effective in multiple sclerosis with relapses: results of a randomised, placebo-controlled Phase II study. ECTRIMS (2004) abstracts.
  • MCALLISTER LD, BEATTY PG, ROSE J: Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant. (1997) 19(4):395–397.
  • MARMONT AM: Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells (1994) 12(1):125–135.
  • MANDALFINO P, RICE G, SMITH A, KLEIN JL, RYSTEDT L, EBERS GC: Bone marrow transplantation in multiple sclerosis. J. NeuroL (2000) 247(9):691–695.
  • BLANCO Y, SAIZ k CARRERAS E, GRAUS F: Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol (2005) 4(1):54–63.
  • MANCARDI GL, SACCARDI R, FILLIPPI M et al.; ITALIAN GITMO-NEURO INTERGROUP ON AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS: Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology (2001) 57(1):62–68.
  • FASSAS A, PASSWEG JR, ANAGNOSTOPOULOUS A et al.; AUTOIMMUNE DISEASE WORKING PARTY OF THE EBMT (EUROPEAN GROUP FOR BONE AND MARROW TRANSPLANTATION): Hematopoietic stem cell transplantation for multiple sclerosis. A retrospectivemulticenter study. J. NeuroL (2002) 249(8):1088–1097.
  • SACCARDI R, MANCARDI GL, SOLARI A et al.: Autologous HSCT for severe progressive multiple sclerosis in a multicentre trial: impact on disease activity and quality of life. Blood (2005) 105(6):2601–2607.
  • YONG VW, POWER C, FORSYTH P, EDWARDS DR: Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. (2001) 2(7):502–511.
  • BRUNDULA V REWCASTLE NB, METZ LM, BERNARD CC, YONG VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain (2002) 125(Pt 6):1297–308.
  • POPOVIC N, SCHUBART A. GOETZ BD, ZHANG SC, LININGTON C, DUNCAN ID: Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol (2002) 51(2):215–223.
  • METZ LM, ZHANG Y, YEUNG M et al: Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol (2004) 55(5):756.
  • ELKAYAM O, YARON M, CASPI D: Minocycline-induced autoimmune syndromes: an overview. Semin. Arthritis Rheum. (1999) 28(6):392–397.
  • MORINI M, ROCCATAGLIATA L, DELLEVA R et al: Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. NeuroimmunoL (2004) 148(1-2):146–153.
  • MARRACCI GH, MCKEON GP, MARQUARDT WE, WINTER RW, RISCOE MK, BOURDETTE DN: Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J. Neurosci. Res. (2004) 78(3):362–370.
  • YADAV V, MARRACCI G, LOVERA J et al: Lipoic acid in multiple sclerosis: a pilot study. Mult. Scler. (2005) 11(2):159–165.
  • GATELY MK, RENZETTI LM, MAGRAM J et al: The interleukin-12/ interleukin-12-receptor system: role in normal and pathologic immune responses. Ann. Rev. Immunol (1998) 16:495–521.
  • FERRANTE P, FUSI ML, SARESELLA M et al.: Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. Immunol (1998) 160(3):1514–1521.
  • BROK HP, VAN MEURS M, BLEZER E et al: Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J. Immunol (2002) 169(11):6554–6563.
  • BAGGIOLINI M: Chemokines and leukocyte traffic. Nature (1998) 392(6676):565–568.
  • COLUMBA-CABESAS S, SERAFINI B, AMBROSINI E et al: Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for diseaseregulation. NeuroimmunoL (2002) 130(1-2):10–21.
  • SORENSEN TL, TREBST C, KIVISAKK P et al: Multiple sclerosis: a study of CXCL10 and CXCR3 localization in in the inflamed central nervous system. J. Neuroimmunol. (2002) 127(1-2):59–68.
  • PITT D, WERNER P, RAINE CS: Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. (2000) 6(1):67–70.
  • SMITH T, GROOM k ZHU B, TURSKI L: Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. (2000) 6(1):62–66.
  • DEBOBO MW, LE GUERN J, CANTON T, DOBLE A, PRADIER L: Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur. j Pharmacol (1993) 235(2-3):283–289.
  • GILGUN-SHERKI Y, PANET H, MELAMED E, OFFEN D: Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res. (2003) 989(2):196–204.
  • KALKERS NF, BARKHOF F, BERGERS E, VAN SSHIJNDEL R, POLMAN CH: The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler. (2002) 8(0:532–533.
  • WALLSTROM E, DIENER P, LJUNGDAHL A. KHADEMI M, NILSSON CG, OLSSON T: Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J. NeuroL Sci. (1996) 137(2):89–96.
  • ABRAHAM G, SOLYOM S, CSUZDI E et al: New non competitive AMPA antagonists. Bioorg. Med. Chem. (2000) 8(8):2127–2143.
  • ARIAS RL, TASSE JR, BO MR: Neuroprotective interaction effects of NMDA and AMPA receptor antagonists in an in vitro model of cerebral ischemia. Brain Res. (1999) 816(2):299–308.
  • STRAHLENDORF JC, BRANDON T, MILES R, STRAHLENDORF HK: AMPA receptor-mediated alterations of intracellular calcium homeostasis in rat cerebellar Purkinje cells in vitro: correlates to dark cell degeneration. Neurochem. Res. (1998) 23(11):1355–1362.
  • NISIM AA, HERNANDEZ CM, COHEN RW: The neuroprotective effects of non-NMDA antagonists in the cerebellum of the spastic Han Wistar mutant. Dev. Neurosci. (1999) 21(1):76–86.
  • SMITH T, GROOM A, ZHU B, TURSKI L: Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. (2000) 6(1):62–66.
  • STYS PK, WAXMAN SG, RANSOM BR: Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na* channels and Na(*)-Ca2* exchanger. Neurosci. (1992) 12(2):430–439.
  • CRANER MJ, NEWCOMBE J, BLACK JA, HARTLE C, CUZNER ML, WAXMAN SG: Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na*/Ca2* exchanger. Proc. Natl. Acad. Sci. USA (2004) 101(21):8168–8173.
  • CRANER MJ, HAINS BC, LO AC, BLACK JA, WAXMAN SG: Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain (2004) 127(Pt 2):294–303.
  • BECHTOLD DA, KAPOOR R, SMITH KJ: Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann. Neurol (2004) 55(5):607–616.
  • CRANER MJ, DAMARJIAN TG, LIU S et al.: Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia (2005) 49(2):220–229.
  • LO AC, SAAB CY, BLACK JA, WAXMAN SG: Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J. Neurophysiol (2003) 90(5):3566–3571.
  • FOX P, BAIN PG, GLICKMAN S, CARROLL C, ZAJICEK J: The effect of cannabis on tremor in patients with multiple sclerosis. Neurology (2004) 62(7):1105–1109.
  • ZAJICEK J, FOX P, SANDERS H et al.; UK MS RESEARCH GROUP: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (2003) 362(9395):1517–1526.
  • VANEY C, HEINZEL-GUTENBRUNNER M, JOBIN P et al: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. (2004) 10(4):417–424.
  • PRYCE G, AHMED Z, HANKEY DJ et al: Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 126(Pt 10):2191–2202.
  • JELKMANN W, METZEN E: Erythropoietin in the control of red cell production. Ann. Anat. (1996) 178(5):391–403.
  • CERAMI A, BRINES M, GHEZZI P, CERAMI C, ITRI LM: Neuroprotective properties of epoetin-a. Nephrol Dial. Transplant. (2002) 17\(Suppl. 1):8–12.
  • MARTI HH: Erythropoietin and the hypoxic brain. J. Exp. Biol. (2004) 207(Pt 18):3233–3242.
  • AGNELLO D, BIGINI P, VILLA P et al.: Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. (2002) 952(1):128–134.
  • ZHANG J, LI Y, CUI Y et al.: Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. (2005) 1034(1-2):34–39.
  • MCTIGUE DM, HORNER PJ, STOKES BT, GAGE FH: Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J. Neurosci. (1998) 18(14):5354–5365.
  • DIEM R, SATTLER MB, MERKLER D et al.: Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain (2005) 128(Pt 2):375–385.
  • LI W, MAEDAY, YUAN RR, ELKABES S, COOKS, DOWLING P: Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann. Neurol (2004) 56(0:767–777.
  • EHRENREICH H, AUST C, KRAMPE H et al.: Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab. Brain Dis. (2004) 19:(3-4):195–206.
  • WOLSWIJK G, MUNRO PM, RIDDLE PN, NOBLE M: Origin, growth factor responses, and ultrastructural characteristics of an adult-specific glial progenitor cell. Ann. NY Acad. Sci. (1991) 633:502–504.
  • BOZZALI M, WRABETZ L: Axonal signals and oligodendrocyte differentiation. Neurochem. Res. (2004) 29(5):979–988.
  • WILSON HC, ONISCHKE C, RAINE CS: Human oligodendrocyte precursor cells in vitro: phenotypic analysis and differential response to growth factors. Glia (2003) 44(2):153–165.
  • LINKER RA, MAURER M, GAUPP S et al.: CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. (2002) 8(6):620–624.
  • LIU X, YAO DL, WEBSTER H: Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult. Scler. (1995) 1(1):2–9.
  • LI M, SENDTNER M, SMITH A: Essential function of LIF receptor in motor neurons. Nature (1995) 378(6558):724–727.
  • BUTZKEUVEN H, ZHANG JG, SOILU-HANNIEN M et al.: LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat. Med. (2002) 8(6):613–619.
  • FRANKLIN RJ, HINKS GL, WOODRUFF RH, O'LEARY MT: What roles do growth factors play in CNS remyelination? Prog-. Brain Res. (2001) 132:185–193.
  • BLAKEMORE WF, GILSON JM, CRANG AJ: Transplanted glial cells migrate over a greater distance and remyelinate demyelinated lesions more rapidly than endogenous remyelinating cells. J. Neurosci. Res. (2000) 61(3):288–294.
  • WINDREM MS, NUNES MC, RASHBAUM WK et al.: Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nat. Med. (2004) 10(1):93–97.
  • BACHELIN C, LACHEPELLE F, GIRARD C et al.: Efficient myelin repair in the macaque spinal cord by autologous grafts of Schwann cells. Brain (2005) 128(Pt 3):540–549.
  • BRUSTLE O, JONES KN, LEARISH RD et al.: Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science (1999) 285(5428):754–756.
  • LIU S, QU Y, STEWART TJ et al: Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. Proc. Natl Acad. Sci. USA (2000) 97(11):6126–6131.
  • GLASER T, PEREZ-BOUZA A, KLEIN K, BRUSTLE 0: Generation of purified oligodendrocyte progenitors from embryonic stem cells. FASEB J. (2005) 19(1):112–114.
  • WHETTEN-GOLDSTEIN K, SLOAN FA, GOLDSTEIN LB, KULAS ED: A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult. Scler. (1998) 5:419–425.
  • PROSSER LA, KUNTZ KM, BAR-OR A, WEINSTEIN MC: Cost-effectiveness of interferon-Bla, interferon-Bib, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health (2004) 5:554–568.
  • GOLD MR, SIEGEL JE, RUSSEL LB, WEINSTEIN M: Cost-effectiveness in health and medicine. Oxford University Press, New York, USA (1990.

Websites

  • http://www.aventis.com
  • http://www.nationalmssociety.org
  • http://www.nice.org.uk/pdfl Multiple°/020Sclerosi0/020Final°/020Guidan ce.pdf Technology Appraisal No. 32. — guidance on the use of beta interferon and glatiramer acetate for the treatment of multiple sclerosis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.